Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Trial for the optimization of risk assessment and therapy success prediction in patients with early breast cancer by the use of biomarkers in advance to therapy decision-making to personalize therapies.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Induction Therapy | Experimental | The kind of induction therapy is dependent on the respective sub-protocol. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Induction therapy | Other | The intervention is dependent on the respective sub-protocol and can include either endocrine therapy, neoadjuvant chemotherapy or targeted therapy. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Identification of a responder sub-population with intermediate and high risk, which due to therapy has outcome comparable to HR+/RS≤11 | In order to identify patients that are at comparable low risk as hormone receptor positive, HER2 negative patients with low Recurrence Score, any sub-population across the sub-trials will be compared to this risk group. | 8 years |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival | 8 years |
| Measure | Description | Time Frame |
|---|---|---|
| Any pre-specified outcome measure is defined within the sub-protocols. | Toxicity and cost efficacy are common endpoints of all sub-protocols. Additional "translational research" questions occurring during the trial will be defined in sub-protocols. | 8 years |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nadia Harbeck, Prof. Dr. | Breast Center of the University of Munich (LMU) Universitätsfrauenklinik Großhadern, Munich, Germany | Principal Investigator |
| Ulrike Nitz, Prof. Dr. | Ev. Krankenhaus Bethesda Brustzentrum Niederrhein, Mönchengladbach, Germany | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Breast Center of the University of Munich (LMU) Universitätsfrauenklinik Großhadern | Munich | Bavaria | 81377 | Germany | ||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23958221 | Background | Hofmann D, Nitz U, Gluz O, Kates RE, Schinkoethe T, Staib P, Harbeck N. WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial. Trials. 2013 Aug 19;14:261. doi: 10.1186/1745-6215-14-261. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Ev. Krankenhaus Bethesda Brustzentrum Niederrhein |
| Mönchengladbach |
| North Rhine-Westphalia |
| 41061 |
| Germany |
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D020360 | Neoadjuvant Therapy |
| ID | Term |
|---|---|
| D003131 | Combined Modality Therapy |
| D013812 | Therapeutics |
Not provided
Not provided